Analyst firms · Bernstein · BMRN
Bernstein BMRN price target and rating history
BioMarin Pharmaceutical Inc. (BMRN) · Health Care
Bernstein rates BioMarin Pharmaceutical Inc. (BMRN) Outperform with a $110 price target, as of its latest action on Aug 20, 2024. It has published 3 rating actions on BMRN since March 2023, including 2 upgrades and 0 downgrades. Across 9 firms with a BMRN price target in the last 12 months, the median target is $88.
- Current rating
- Outperform
- Price target
- $110
- Median target, all firms
- $88
- Actions on BMRN
- 3
Bernstein price target on BMRN
Every Bernstein rating on BMRN
- Aug 20, 2024
- Oct 23, 2023
- Mar 21, 2023
How other firms rate BMRN
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| UBS | Buy | $88 | Oct 15, 2026 |
| Raymond James | Strong Buy | $109 | Oct 12, 2026 |
| BMO Capital Markets | Outperform | $98 | Aug 19, 2026 |
| Citigroup | Buy | $75 | May 19, 2026 |
| Goldman Sachs | Neutral | $69 | May 11, 2026 |
| Morgan Stanley | Overweight | $120 | Apr 27, 2026 |
| Barclays | Overweight | $80 | Jan 28, 2026 |
| Canaccord Genuity | Buy | $98 | Jan 20, 2026 |
| Leerink Partners | Market Perform | $60 | Dec 3, 2025 |
Questions about Bernstein and BMRN
- What is Bernstein's price target for BMRN?
- Bernstein's latest stated price target for BioMarin Pharmaceutical Inc. (BMRN) is $110, from its action on Aug 20, 2024.
- What is Bernstein's rating on BMRN?
- Bernstein rates BMRN Outperform, a bullish rating, as of Aug 20, 2024.
- When did Bernstein last change its view on BMRN?
- On Aug 20, 2024, Bernstein upgrades to Outperform from Mkt Perform, price target $94 to $110.
- How does Bernstein's BMRN target compare with other analysts?
- Across 9 firms with a BMRN price target in the last 12 months, the median target is $88.
More BMRN rating histories
All Bernstein ratingsBMRN news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.